LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2022

Conditions
COVID-19Coronavirus Disease 2019Covid19COVID-19 Pneumonia
Interventions
DRUG

LB1148

LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.

DRUG

Placebo

Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.

Sponsors
All Listed Sponsors
lead

Leading BioSciences, Inc

INDUSTRY